# Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

> **NCT06938867** · PHASE1,PHASE2 · RECRUITING · sponsor: **SNIPR Biome Aps.** · enrollment: 24 (estimated)

## Conditions studied

- E Coli Infections
- Allogenic Transplant Patients

## Interventions

- **BIOLOGICAL:** SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli
- **OTHER:** Placebo 10 mL

## Key facts

- **NCT ID:** NCT06938867
- **Lead sponsor:** SNIPR Biome Aps.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-25
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06938867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06938867, "Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06938867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*